Ideaya Bio­sciences re­it­er­at­ed its goal of be­com­ing a “glob­al leader” in pre­ci­sion on­col­o­gy over the next decade as it shared da­ta from three ear­ly- to mid-stage can­cer tri­als.

Since its in­cep­tion a decade ago, the Cal­i­for­nia biotech has fo­cused on pur­su­ing new tar­gets, nar­row­ing down pa­tient bio­mark­ers and ex­plor­ing “trans­for­ma­tive” com­bi­na­tions in can­cer, Ideaya CEO Yu­jiro Ha­ta said Mon­day on its R&D day call. He be­lieves the com­pa­ny has de­vel­oped “one of the broad­est and deep­est pipelines” with­in pre­ci­sion on­col­o­gy.

Ideaya kicked off its ten-year an­niver­sary, de­tail­ing re­sults from a Phase 2 study of darovasert­ib in pa­tients who’ve had surgery for pri­ma­ry uveal melanoma, a form of rare eye can­cer. The drug is de­signed to se­lec­tive­ly in­hib­it pro­tein ki­nase C.

Pres­i­dent Don­ald Trump is look­ing to strike more deals with trade part­ners and says he “may be will­ing” to ex­empt some phar­ma­ceu­ti­cal prod­ucts from fu­ture tar­iffs.

An ex­ec­u­tive or­der re­leased last week es­tab­lish­es a new list of prod­ucts, dubbed An­nex III, that could face a 0% rec­i­p­ro­cal tar­iff rate de­pend­ing on the deal. Items list­ed un­der An­nex III in­clude an ar­ray of phar­ma­ceu­ti­cal prod­ucts such as cell ther­a­pies, cer­tain vac­cines, an­tibi­otics and oth­er chem­i­cals and hor­mones.

The Fri­day or­der de­fined the phar­ma prod­ucts list­ed un­der An­nex III as “non-patent­ed ar­ti­cles for use in phar­ma­ceu­ti­cal ap­pli­ca­tions.”

Yet no fur­ther de­tails were giv­en, sug­gest­ing that brand­ed drugs with ex­pired patents could be ex­empt­ed from tar­iffs if they fall un­der the An­nex III list. Al­ter­na­tive­ly, the ad­min­is­tra­tion could sim­ply be defin­ing gener­ic phar­ma­ceu­ti­cals as “non-patent­ed” drugs, Mol­lie Sitkows­ki, a trade com­pli­ance part­ner at US law firm Fae­gre Drinker, told End­points News. 

Plus, news about Anavex, Al­ny­lam, Rap­port Ther­a­peu­tics, Di­anthus Ther­a­peu­tics, Ul­tragenyx, Atom Ther­a­peu­tics, Alchemab, Bio­Marin, Am­gen, Ky­owa Kirin and Bris­tol My­ers Squibb:

🤧 Re­gen­eron’s al­ler­gy drugs clear Phase 3 tri­als: The com­pa­ny’s al­ler­gen-block­ing an­ti­body can­di­dates met the pri­ma­ry end­point of im­prove­ment in oc­u­lar itch in two sep­a­rate reg­is­tra­tional stud­ies in peo­ple with al­ler­gies to cats and birch. Par­tic­i­pants in the cat study had an av­er­age 52% re­duc­tion in oc­u­lar itch, while those in the birch study had an av­er­age 51% re­duc­tion. — Ay­isha Shar­ma

No­var­tis said Tues­day that it would buy Tour­ma­line Bio for $1.4 bil­lion in a bid to re­vi­tal­ize its car­dio­vas­cu­lar of­fer­ing.

The Swiss phar­ma said it would pay $48 per share in cash for Tour­ma­line, a pre­mi­um of near­ly 60% to the biotech’s clos­ing price on Mon­day.

Tour­ma­line’s main as­set, an an­ti-IL-6 an­ti­body called pacibek­i­tug, gen­er­at­ed promis­ing mid-stage da­ta in ath­er­o­scle­rot­ic car­dio­vas­cu­lar dis­ease in May. And No­var­tis is look­ing to re­vi­tal­ize its heart dis­ease drug pipeline, con­sid­er­ing the patent for its heart fail­ure block­buster En­tresto is set to ex­pire soon. En­tresto is No­var­tis’ best­selling drug, mak­ing over $4 bil­lion last year.